UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2010

 

 

PSIVIDA CORP.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Delaware   000-51122   26-2774444

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

400 Pleasant Street

Watertown, MA 02472

(Address of Principal Executive Offices) (Zip Code)

(617) 926-5000

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.

The annual meeting of stockholders of pSivida Corp. (the “Company”) was held on December 9, 2010. The stockholders elected each of the Company’s nominees for director, approved the stock option grants to Dr. Ashton, approved the stock option grants to each of the Company’s non-executive directors and ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2011. The proposals below are described in detail in the Company’s definitive proxy statement filed with the SEC on October 25, 2010.

The results are as follows:

Proposal 1. Election of Directors:

 

DIRECTOR NOMINEE

   FOR      WITHHELD      BROKER NON-VOTES  

David J. Mazzo

     6,767,348         169,071         4,087,430   

Paul Ashton

     6,781,905         154,514         4,087,430   

Paul A. Hopper

     6,028,337         908,082         4,087,430   

Michael Rogers

     6,682,524         253,895         4,087,430   

Peter G. Savas

     4,925,087         2,011,332         4,087,430   

Proposal 2. Approval of Stock Option Grants to CEO Paul Ashton:

 

FOR

     6,103,567   

AGAINST

     748,040   

ABSTAIN

     84,812   

BROKER NON-VOTES

     4,087,430   

Proposal 3. Approval of Stock Option Grants to non-executive directors:

 

DIRECTOR NOMINEE

   FOR      AGAINST      ABSTAIN      BROKER NON- VOTES  

Paul A. Hopper

     4,139,367         2,713,697         83,355         4,087,430   

Michael Rogers

     5,018,104         1,809,710         108,605         4,087,430   

Peter G. Savas

     4,393,912         2,474,790         67,717         4,087,430   

David J. Mazzo

     5,074,017         1,721,134         141,268         4,087,430   


Proposal 4. Ratification of appointment of Deloitte & Touche LLP:

 

FOR

     10,444,007   

AGAINST

     467,537   

ABSTAIN

     112,305   


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PSIVIDA CORP.
Date: December 13, 2010     By:  

/S/    LORI FREEDMAN        

     

Lori Freedman, Vice President, Corporate Affairs,

General Counsel and Secretary